1. Nonalcoholic Steatohepatitis (NASH) in OB-OB Mice Treated with YHK (YojoHenshiKo): Effects on Peroxisome Proliferator-Activated Receptors (PPARs) and Microsomal Triglyceride Transfer Protein (MTP)
researcher：J. T. Stefano, C. P. M. S. de Oliveira, M. L. Corrˆea-Giannella, V. M. R. de Lima, S. V. de S´a, E. P. de Oliveira, E. S. de Mello, D. Giannella-Neto, , V. A. F. Alves, J. T. Stefano, F. J. Carrilho
The research, on effect of YHK to Nash sufferer, was published on "Liver International" in March 2007. We found in the test, YHK can prevent NASH, lose weight, and reduce visceral fat and serum concentrations of aminotransferases to limit hepatocyte lipid accumulation. The protective effect of YHK is obvious, and more……
2. YHK(YojoHenshiKo), a novel Chinese herbal, prevents nonalcoholic steatohepatitis in ob-ob mice fed a high fat or methionine-choline-deficient diet
researcher：Lima V.M., Oliveira C.P., Sawada L.Y., Barbeiro H.V., Mello E.S., Soriano F.G., Alves V.A.F., Caldwell S.H., Carrilho F.J.
Research on effect of YHK on reducing reactive oxygen species (ROS) in Nash was published on Medical Journal "Digestive Diseases and Sciences" on Mar.30th, 2007. The test result shows that, YKH can blunt the development of macrosteatosis in NASH, significantly reduce oxidative stress and diminish weight gain in obesity case,and more…….
3.YHK(YojyoHenshiKo) Improves Transaminases in Nonalcoholic Steatohepatitis (NASH): A Randomized Pilot Study
researcher：N Chande, M. Laidlaw, P Adams and P Marotta
The research, titled “YHK improves transaminases in NASH”, was released in Canada on Mar.19th-22nd, 2005. Except for anti-inflammatory and antifibrotic functions, YHK can also achieve improvement in transaminases in viral hepatitis cases. It effectively reduced ALT (GPT) value in patients with NASH,,and more…….
4. EFFECT OF K-17.22, A NOVEL PHYTOTERAPEUTIC AGENT, ON DNA SYNTHESIS AND LIVER ENZYME RELEASE IN EXPERIMENTAL LIVER DAMAGE
researcher：F Marotta Y Rahman-Shield E Minelli A Helmy P Safran M Harada
Research on YHK‘s beneficial effect on plasma and liver tissue parameters of hepatotoxicity as well as on liver DNA synthesis activity was released in Yamanashi, Japan during Nov.14th to 15th, 2002. The data shows that, YHK have protective effect in liver toxicity case. The research is helpful on treatment of HCV, especially in view of HCC (Hepatocellular Carcinoma) transformation,and more…….
5. IS THERE ANY LIVER ANTI-FIBROTIC EFFECT OF K-17.22? AN EXPERIMENTAL STUDY WITH IMMUNOHISTOCHEMICAL ANALYSIS IN A RAT MODEL
researcher：F Marotta Y Rahman-Shield E Minelli A Helmy E.Oliva P Safran M. Harada(Harada Hospital, Saitama, Japan)
Study on anti-fibrosis effect of YHK was released in Yamanashi, Japan during Nov.14th to 15th, 2002. Liver fibrosis in chronic liver disease is not a simple deposition of excess but it implies a change in the type of matrix molecules. The result of test showed a potent antifibrotic effect of YHK by reducing fat deposition in hepatocyte and number of activated stellate cells,and more…….
6. YHK, A NOVEL HERBAL REMEDY WITH EFFECTIVE ANTIFIBROTIC ACTION, IN CHRONIC LIVER DISEASE: A PILOT CLINICAL STUDY AIMING TO A SUCCESSFUL INTEGRATIVE MEDICINE DEVELOPMENT
researcher：M. Harada(Harada Hospital, Saitama, Japan) F. Marotta(Hepato-GI Dept., S. Giuseppe Hosp., Milano, Italy) S.H. Sha(Inst. Health Care Oriental Herbs & Med, Tokyo, Japan) E. Minelli(WHO-Cntr., for Traditional Medicine, University of Milano, Italy)
The research on effective antifibrotic action of YHK in chronic liver disease was released in Yamanashi, Japan on Nov.14th to 15th, 2002. Chronic liver disease represents one of the major causes of mortality and morbidity worldwide. In the end of this experiment, we found, transaminases level significantly decreased and value of ALT (GPT) fell into normal in all patients within first two weeks, and we also see an improvement of liver fibrosis, and more…….
7. A Nutritional Approach with Herbal Remedy K-17.22 Delays the Onset of Spontaneous Chronic Pancreatitis
researcher：Marotta F(Hepato-GI Department, S. Giuseppe Hospital. Milan, Italy) Harada M(Harada Hospital, Saitama, Japan ) Bertuccelli J Rouge A Anzulovic H Yanaihara N(Yanaihara Institute Inc., Shizuoka, Japan) Ideo G
The research on “YHK Delays the Onset of Spontaneous Chronic Pancreatitis” was published in Como, Italy on Sep.20th to 22nd, 2001. CP is a progressive disease. There are no available and validated therapeutic options. But our test shows that, YHK exerts powerful protective and therapeutic effect against the progression of experimental CP,and more…….
8. Effect of “YHK(YojyoHenshiKo）”, in patients with hepatic diseases
researcher：S. Sha (Institute of Health Care with Oriental Herb and Medicine, Tokyo, Japan) M.Harada(Harada Hospital, Saitama, Japan) N. Yanaihara (Yanaihara Institute Inc., Shizuoka, Japan)
The research, titled “YHK’s effect on liver hepatitis disease”, was released in Maui, Hawai on Dec.16th -20th, 2001, aiming to test effect of YHK on reducing serum ALT(GPT) and AST(GOT) level of the patients with liver diseases, such as HBV, HCV, Alcoholic liver, Drug abused liver, Fatty liver, Cirrhosis, Liver cancer and so on. The result shows YHK successfully reduced levels of ALT (GPT) and AST (GOT) of patients. And no side effect was observed during the treatment, and more…….
9. The Effect of the Tablets, YHK(YojyoHenshiKo）
researcher：S. Sha (Institute of Health Care with Oriental Herb and Medicine, Tokyo, Japan) M.Harada(Harada Hospital, Saitama, Japan) N. Yanaihara
(Yanaihara Institute Inc., Shizuoka, Japan)
The research on influences of YHK to ALT (GPT) in the blood and AST (GOT) concentration was published in Osaka, Japan on Nov.10th 2001. The levels of the ALT (GPT) and AST (GOT) of the patients have remarkably decreased after taking YHK for 10 days. And no side effect was found in the test, and more…….
10. The Effect of the Yojyo Hen Shi Ko for the liver diseases–Specially for the Hepatitis type C
researcher：Masayoshi Harada Noboru Yanaihara F. Marotta Ichirou Yoshijima Hideyuki shimizu Katsumasa Hosokawa Yoshitaka Tsuji Yoshiaki Harada Sha Shin Han
In Japan, the mortality of liver cancer is increasing year by year. The morbidity of liver cancer from the hepatitis C has three times more than that of the hepatitis B. At present, the interferon is effective medicine for the hepatitis C. However, 70 % of Japanese are sero-type 1 and 30% are sero-type 11. But interferon is not so effective for the sero-type 1 patients which account 70% of total population in Japan. In the research published in Saitama, Japan on Oct.20th, 2001, we found YHK can successfully reduce level of ALT (GPT) to normal in 10-14 days,and more…….
11. BENEFICIAL EFFECT OF A CONTROLLED CHINESE HERBAL REMEDY
researcher：
Marotta A.Rouge H.Anzulovic M.Harada G.M.Ideo K.Kajikawa N.Yahaihara G.Princess G. Ideo α-Ω Techonolab
In the first test, we test effect of YHK in CCL4 (carbon tetrachloride)-induced liver toxicity, which was published in Florence, Italy during Oct.12th-13th, 2001. In the test, YHK exerts a highly sparing and prolonged effect (either preventive or therapeutic) on GSH (Glutathione) depletion and on the conjugate liver GSH/GSSG redox system in CCL4-induced liver injury.
In the second test, a nutritional approach with YHK on endogenous hepatic antioxisant system was tested. YHK enables a recovery of liver blood flow in sufferers. It offers a boosting ability on endogenous free radicals scavengers array,and more…….
12. EFFECT OF “YOJYO HENSHIKO: A NEW CHINESE HERB PRESCRIPTION” ON SERUM ALT(GPT) AND AST(GOT) LEVELS IN PATIENTS WITH HEPATIC DISEASES
researcher：S. Sha (Institute of Health Care with Oriental Herb and Medicine, Tokyo, Japan) M. Harada (Harada Hospital, Saitama, Japan ) N. Yanaihara (Yanaihara Institute Inc., Shizuoka, Japan)
Details-please click here
13. [Effect and Application of Yojyo Henshiko]
researcher：S. Sha (Institute of Health Care with Oriental Herb and Medicine, Tokyo, Japan) N. Yanaihara (Yanaihara Institute Inc., Shizuoka, Japan)
Details-please click here
14. Effect of “Yojyo Henshiko, a new Chinese herb Prescription”on serum ALT(GPT) and AST(GOT) levels in patients with hepatic diseases
researcher ：S. Sha (Institute of Health Care with Oriental Herb and Medicine, Tokyo, Japan) M.Harada(Harada Hospital, Saitama, Japan) N. Yanaihara (Yanaihara Institute Inc., Shizuoka, Japan)
Details-please click here
15. Clinical application and efficacy of a new Chinese medical herb prescription:“Yojyo Henshiko”
researcher ：S. Sha (Institute of Health Care with Oriental Herb and Medicine, Tokyo, Japan) N. Yanaihara (Yanaihara Institute Inc., Shizuoka, Japan)
Details-please click here
In the above research(12th-15th), we study on effect of YHK on reducing ALT (GPT) and AST (GOT) in patients with liver disease. It was done Jun.2nd -7th, 2000. It clearly shows the effect of YHK in lowering the enhanced serum levels of ALT (GPT) and AST (GOT) in the patients with hepatic diseases. Any side effects were not observed during the treatment. |
